The award is the first following a funding announcement last year to support typhoid fever diagnostic test development.

Biosynex SA (FR:ALBIO) has released an update. Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test ...

Chembio Diagnostics, Inc. (CEMI) becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA ...

BIOSYNEX SA BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY 23-Oct-2024 / 18:00 CET/CEST Dissemination of a French ...

STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and ...

A manufacturer of rapid diagnostic tests in Hauppauge has paid $500,000 to end an investigation by the U.S. Securities and Exchange Commission, according to a securities filing. Chembio Diagnostics ...

* FIRST SUPPLIES OF THE RAPID SEROLOGY TEST BIOSYNEX COVID-19 BSS TO ANALYTICAL LABORATORIES AND FRENCH HOSPITALS Source text: bit.ly/2RejCSz Further company coverage: ...

A financially strapped Hauppauge-based manufacturer of diagnostic tests is being purchased by a French test maker for $17.2 million in cash, officials said. Chembio Diagnostics Inc. has signed a ...

PARIS – Biosynex SA signed a binding offer to acquire 100% of the stock in Avalun SAS, a company developing the Labpad in vitro diagnostic device that provides rapid biological test results from small ...

STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has ...